PMP Use Mandate Letter
BehavioralA letter with reminders about the mandate to check the PMP when prescribing opioids.
NCT Number: NCT04628832
Despite an enormous policy response, opioid prescribing remains well above historical levels and harms from opioids continue to mount. Nearly all states have Prescription Monitoring Programs (PMPs) to facilitate safer prescribing of opioids and other drugs, but research suggests these systems only deliver benefits when health care professionals are required to use them. Even with PMP mandates in place, providers may be unaware of the dangers of co-prescribing opioids with benzodiazepines or gabapentinoids, which include increased risk of overdose and death. Working with the Minnesota state government, the investigators will mail letters to guideline-discordant opioid prescribers that either highlight an upcoming legally mandated requirement to check the PMP before prescribing an opioid, inform and educate providers about patients filling concurrent prescriptions and the dangers of such co-prescribing, or both. Study participants will be randomized to receive no intervention or one of the three treatment letters. Using administrative data, the investigators will track effects of the letters on not only prescribing but also PMP usage and queries. Findings form the multiplicity of treatment messages and outcomes will shed light on the mechanisms driving overprescribing. Results will inform future work by state and local policymakers to make opioid prescribing safer.
Looking for future studies?
Notify MeAll sexes
Interventional
Not applicable
Minnesota Board of Pharmacy, Minneapolis, Minnesota, United States
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
A letter with reminders about the mandate to check the PMP when prescribing opioids.
A letter with information about the prescriber's patients who received co-prescriptions. The letters will provide clinical background on the harms of co-prescribing and encourage prescribers to avoid co-prescribing in the future.
A letter combining the content of the PMP Use Mandate Letter and the Prescribing Information Letter. This letter will remind prescribers about the PMP use mandate and provide information about the prescriber's patients who received co-prescriptions.
Time frame: 60 days
The number of patients with co-prescriptions from the prescriber in the 60 days after the letters are sent.
Time frame: 60 days
Indicator for whether the prescriber checks the PMP at least once in the 60 days after the letters are sent.
Columbia University
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03629197
Chronic Pain, Communication Research
Sacramento, California, United States
View Trial DetailsNCT05506878
Abdominal Pain, Agnosia
Pittsburgh, Pennsylvania, United States
View Trial DetailsNCT04873401
COVID-19, Chemically-Induced Disorders
New York, United States
View Trial DetailsNCT05351905
Cannabis, Chemically-Induced Disorders
Toronto, Ontario, Canada
View Trial Details